VeinWay Ltd is a medical device company founded in 2020 by Jordan Pollack within the MEDX Xelerator incubator as a response to the clinical unmet need focused on Chronic Venous Occlusions (CVOs). Discussions conducted between 2021-2022 with established physicians from Europe, Israel and the US revealed that crossing CVOs is one of the largest unmet needs in interventional radiology today, with failure rates estimated between 10%-17%. Because of how cumbersome it is to recanalize chronically occluded veins, few physicians perform the procedure and thus, only around 10-13% of patients who need a venous stent actually receive one. VeinWay's Traversa delivers the first dedicated device designed for venous recanalization that will improve outcomes and allow physicians to reliably, safely and easily complete endovascular procedures in a timely manner for the effective treatment of CVOs. The Traversa is an enabling technology which will disrupt the market by democratizing physician access to the treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or that are currently in development. All other solutions are either off-label tools that have a high risk of perforation, or standard crossing tools with no specific indication or features for venous recanalization. Physicians use them as workarounds when the procedure fails with standard guidewires. In contrast, Traversa is the first tool designed specifically for crossing CVOs, allowing for an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time.